QIAGEN: Period of uncertainty with M&A as sole source of upside? | BUY | EUR32 vs. EUR39 (+34%)
QIAGEN - BUY | EUR32 vs. EUR39 (+34%)Period of uncertainty with M&A as sole source of upside?
Another weak quarter should lead to another guidance downgrade
FV adjusted to EUR32 vs EUR39 (-18%)
It will take time to restore confidence
NGS strategy shift and restructuring makes QIA a target?
Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.